Study on the therapeutic status of 1242 hospitalized acute myocardial infarction patients in Beijing.
- Author:
Shuo-ren WANG
1
;
Hong-xu LIU
;
Dong ZHAO
;
Yan LEI
;
Wei WANG
;
Ju-ju SHANG
;
Yu-tao FANG
;
Zai-xiang SHI
;
Yi HUANG
;
Qing-lang LI
;
null
Author Information
- Publication Type:Journal Article
- MeSH: China; Cities; Female; Guideline Adherence; Humans; Male; Middle Aged; Myocardial Infarction; therapy; Quality of Health Care
- From: Chinese Journal of Epidemiology 2006;27(11):991-995
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate and analyze the therapeutic level and the existing problems on acute myocardial infarction (AMI) management in Beijing.
METHODSWe collected clinic data of 1242 AMI patients from 12 hospitals in Beijing, from January 2000 to March 2001, using a uniformed questionnaire, and evaluated the status of the diagnosis and treatment of AMI according to the Chinese guidelines issued on Decmeber 2001. Corresponding factors which influencing the mortality were also analyzed by one-way factor and multiple factors analysis methodologies.
RESULTSThe mean age of the 1242 AMI patients was 63.0 years old and about one third of them were under 55 years old. In hospitals, the total mortality was 9.10%. 37.9% of the patients had received therapy of the intravenous thrombolysis and emergency PCI with a total rate of reperfusion therapy as 56.0%. The in-hospital rates of drug use were as follows: Nitrates 90.0%, Aspirin 87.8%, heparin 88.7%, beta-blockers 73.4%, angiotensin converting enzyme inhibitors(ACEI) 77.6%, lipid regulating agents 43.6%. The rate of intravenous therapy of TCM by promoting the blood circulation and supplementing the vital energy was 30.5%. Results from multiple factors analysis showed that the compositive factors which could lower the mortality were reperfusion therapy,lipid regulating agents, intravenous therapy of TCM, beta-blockers, ACEI, lower molecule heparin and digitalis.
CONCLUSIONData from this study showed that there still existed a gap between clinical management on AMI and the guideline in Beijing. To set up a straightway passage of reperfusion therapy, to become more standardized to follow the guideline in undertaking the medical treatment practice, and to go deep into discuss the status of TCM on AMI management seemed the important tasks we are facing.